Using a specialized lab technique, scientists identified early cellular changes that may help drive lung scarring in ...

Tyvaso significantly improved a measure of lung function for IPF patients in a Phase 3 trial, which top-line data showed met ...

Columnist Sam Kirton talks to Scott Staszak, president and CEO of the Pulmonary Fibrosis Foundation, about the need for better research.

Marta Ribeiro Marta graduated from Universidade Fernando Pessoa in Porto with a degree in Communication Sciences and a Masters degree in New Communication Technologies. She has experience in social ...

Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease, which means it worsens over time. Because there’s no cure, the goal is to try and preserve lung function for as long as possible.

According to the National Institutes of Health (NIH), about 100,000 people in the U.S. have pulmonary fibrosis. Between 30,000 and 40,000 new cases are diagnosed every year. While inherited pulmonary ...

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

An experimental oral therapy for idiopathic pulmonary fibrosis (IPF) has been tolerated well in an ongoing Phase 2 clinical trial, according to interim data announced by its developer GRI Bio. “We are ...

Treatment with GRI Bio‘s investigational oral therapy GRI-0621 appears to reduce markers of fibrosis, or scarring, in people with idiopathic pulmonary fibrosis (IPF), according to an interim analysis ...